Vav promoter-tTA conditional transgene expression system for hematopoietic cells drives high level expression in developing B and T cells

Experimental Hematology

Volumn 35, Issue 8, 2007, Pages 1231-1239

  Kim, Won Il ^a,b   Wiesner, Stephen M ^b   Largaespada, David A ^b  

^a Cellular   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; DOXYCYCLINE; LUCIFERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; GENE REPRESSION; LYMPHOPOIESIS; MAST CELL; MASTOCYTOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REGULATORY DNA SEQUENCE; T LYMPHOCYTE; TETRACYCLINE RESPONSIVE ELEMENT; THYMUS; TRANSGENIC MOUSE; VAV GENE;

ANIMALS; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DOXYCYCLINE; GENES, REPORTER; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; LUCIFERASES; MICE; MICE, TRANSGENIC; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-VAV; T-LYMPHOCYTES; TETRACYCLINE;

MUS;

EID: 34447629317     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2007.04.012     Document Type: Article

References (46)

1. Ogilvy S., Elefanty A.G., Visvader J., Bath M.L., Harris A.W., and Adams J.M. Transcriptional regulation of vav, a gene expressed throughout the hematopoietic compartment. Blood 91 (1998) 419-430
2. Ogilvy S., Metcalf D., Gibson L., Bath M.L., Harris A.W., and Adams J.M. Promoter elements of vav drive transgene expression in vivo throughout the hematopoietic compartment. Blood 94 (1999) 1855-1863
3. Ogilvy S., Metcalf D., Print C.G., Bath M.L., Harris A.W., and Adams J.M. Constitutive Bcl-2 expression throughout the hematopoietic compartment affects multiple lineages and enhances progenitor cell survival. Proc Natl Acad Sci U S A 96 (1999) 14943-14948
4. Katzav S., Martin-Zanca D., and Barbacid M. vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells. EMBO J 8 (1989) 2283-2290
5. Keller G., Kennedy M., Papayannopoulou T., and Wiles M.V. Hematopoietic commitment during embryonic stem cell differentiation in culture. Mol Cell Biol 13 (1993) 473-486
6. Zmuidzinas A., Fischer K.D., Lira S.A., et al. The vav proto-oncogene is required early in embryogenesis but not for hematopoietic development in vitro. EMBO J 14 (1995) 1-11
7. Houlard M., Arudchandran R., Regnier-Ricard F., et al. Vav1 is a component of transcriptionally active complexes. J Exp Med 195 (2002) 1115-1127
8. Bustelo X.R., Rubin S.D., Suen K.L., Carrasco D., and Barbacid M. Developmental expression of the vav protooncogene. Cell Growth Differ 4 (1993) 297-308
9. Crespo P., Schuebel K.E., Ostrom A.A., Gutkind J.S., and Bustelo X.R. Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the vav proto-oncogene product. Nature 385 (1997) 169-172
10. Turner M., Mee P.J., Walters A.E., et al. A requirement for the Rho-family GTP exchange factor Vav in positive and negative selection of thymocytes. Immunity 7 (1997) 451-460
11. Costello P.S., Walters A.E., Mee P.J., et al. The Rho-family GTP exchange factor Vav is a critical transducer of T cell receptor signals to the calcium, ERK, and NF-kappaB pathways. Proc Natl Acad Sci U S A 96 (1999) 3035-3040
12. Caloca M.J., Zugaza J.L., Matallanas D., Crespo P., and Bustelo X.R. Vav mediates Ras stimulation by direct activation of the GDP/GTP exchange factor Ras GRP1. EMBO J 22 (2003) 3326-3336
13. Adams J.M., Harris A.W., Strasser A., Ogilvy S., and Cory S. Transgenic models of lymphoid neoplasia and development of a pan-hematopoietic vector. Oncogene 18 (1999) 5268-5277
14. Turner S.D., Tooze R., Maclennan K., and Alexander D.R. Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase. Oncogene 22 (2003) 7750-7761
15. Lee B.H., Williams I.R., Anastasiadou E., et al. FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model. Oncogene 24 (2005) 7882-7892
16. Wiesner S.M., Jones J.M., Hasz D.E., and Largaespada D.A. Repressible transgenic model of NRAS oncogene-driven mast cell disease in the mouse. Blood 106 (2005) 1054-1062
17. Almarza E., Segovia J.C., Guenechea G., Gomez S.G., Ramirez A., and Bueren J.A. Regulatory elements of the vav gene drive transgene expression in hematopoietic stem cells from adult mice. Exp Hematol 32 (2004) 360-364
18. Georgiades P., Ogilvy S., Duval H., et al. VavCre transgenic mice: a tool for mutagenesis in hematopoietic and endothelial lineages. Genesis 34 (2002) 251-256
19. Gossen M., and Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A 89 (1992) 5547-5551
20. Kistner A., Gossen M., Zimmermann F., et al. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci U S A 93 (1996) 10933-10938
21. Geurts A.M., Wilber A., Carlson C.M., et al. Conditional gene expression in the mouse using a Sleeping Beauty gene-trap transposon. BMC Biotechnol 6 (2006) 30
22. Bacher U., Haferlach T., Schoch C., Kern W., and Schnittger S. Implications of NRAS mutations in AML: a study of 2502 patients. Blood 107 (2006) 3847-3853
23. Casey G., Rudzki Z., Roberts M., Hutchins C., and Juttner C. N-ras mutation in acute myeloid leukemia: incidence, prognostic significance and value as a marker of minimal residual disease. Pathology 25 (1993) 57-62
24. Kalra R., Dale D., Freedman M., et al. Monosomy 7 and activating RAS mutations accompany malignant transformation in patients with congenital neutropenia. Blood 86 (1995) 4579-4586
25. Lee Y.Y., Kim W.S., Bang Y.J., et al. Analysis of mutations of neurofibromatosis type 1 gene and N-ras gene in acute myelogenous leukemia. Stem Cells 13 (1995) 556-563
26. Vogelstein B., Civin C.I., Preisinger A.C., et al. RAS gene mutations in childhood acute myeloid leukemia: a Pediatric Oncology Group study. Genes Chromosomes Cancer 2 (1990) 159-162
27. Futatsugi N., and Tsuda M. Molecular dynamics simulations of Gly-12→Val mutant of p21(ras): dynamic inhibition mechanism. Biophys J 81 (2001) 3483-3488
28. Quilliam L.A., Hisaka M.M., Zhong S., et al. Involvement of the switch 2 domain of Ras in its interaction with guanine nucleotide exchange factors. J Biol Chem 271 (1996) 11076-11082
29. Howe L.R., and Marshall C.J. Identification of amino acids in p21ras involved in exchange factor interaction. Oncogene 8 (1993) 2583-2590
30. Largaespada D.A., Brannan C.I., Jenkins N.A., and Copeland N.G. Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nat Genet 12 (1996) 137-143
31. Wilsey J., Zolotukhin S., Prima V., Shek E.W., Matheny M.K., and Scarpace P.J. Hypothalamic delivery of doxycycline-inducible leptin gene allows for reversible transgene expression and physiological responses. Gene Ther 9 (2002) 1492-1499
32. Furuno T., Ma D., van der Kleij H.P., Nakanishi M., and Bienenstock J. Bone marrow-derived mast cells in mice respond in co-culture to scorpion venom activation of superior cervical ganglion neurites according to level of expression of NK-1 receptors. Neurosci Lett 372 (2004) 185-189
33. Tremblay P., Meiner Z., Galou M., et al. Doxycycline control of prion protein transgene expression modulates prion disease in mice. Proc Natl Acad Sci U S A 95 (1998) 12580-12585
34. Holland A.M., Hale M.A., Kagami H., Hammer R.E., and MacDonald R.J. Experimental control of pancreatic development and maintenance. Proc Natl Acad Sci U S A 99 (2002) 12236-12241
35. Demehri S., Corbin A., Loriaux M., Druker B.J., and Deininger M.W. Establishment of a murine model of aggressive systemic mastocytosis/mast cell leukemia. Exp Hematol 34 (2006) 284-288
36. de Boer J., Williams A., Skavdis G., et al. Transgenic mice with hematopoietic and lymphoid specific expression of Cre. Eur J Immunol 33 (2003) 314-325
37. Stewart M., Cameron E., Campbell M., et al. Conditional expression and oncogenicity of c-myc linked to a CD2 gene dominant control region. Int J Cancer 53 (1993) 1023-1030
38. Wildin R.S., Wang H.U., Forbush K.A., and Perlmutter R.M. Functional dissection of the murine lck distal promoter. J Immunol 155 (1995) 1286-1295
39. Zhang D.J., Wang Q., Wei J., et al. Selective expression of the Cre recombinase in late-stage thymocytes using the distal promoter of the Lck gene. J Immunol 174 (2005) 6725-6731
40. Smith C.A., Graham C.M., Mathers K., et al. Conditional ablation of T-cell development by a novel viral ion channel transgene. Immunology 105 (2002) 306-313
41. Cook G.P., Meyer K.B., Neuberger M.S., and Pettersson S. Regulated activity of the IgH intron enhancer (E mu) in the T lymphocyte lineage. Int Immunol 7 (1995) 89-95
42. Greenwald R.J., Tumang J.R., Sinha A., et al. E mu-BRD2 transgenic mice develop B-cell lymphoma and leukemia. Blood 103 (2004) 1475-1484
43. Hess J., Nielsen P.J., Fischer K.D., Bujard H., and Wirth T. The B lymphocyte-specific coactivator BOB.1/OBF.1 is required at multiple stages of B-cell development. Mol Cell Biol 21 (2001) 1531-1539
44. Bockamp E., Antunes C., Maringer M., et al. Tetracycline-controlled transgenic targeting from the SCL locus directs conditional expression to erythrocytes, megakaryocytes, granulocytes, and c-kit-expressing lineage-negative hematopoietic cells. Blood 108 (2006) 1533-1541
45. Radomska H.S., Gonzalez D.A., Okuno Y., et al. Transgenic targeting with regulatory elements of the human CD34 gene. Blood 100 (2002) 4410-4419
46. Parikh C., Subrahmanyam R., and Ren R. Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice. Blood 108 (2006) 2349-2357